Novel Drug Tied to Slowed Disease Progression in Relapsing MS

The novel anti-CD20 monoclonal antibody ublituximab showed greater improvement vs terifulnomide in stabilizing disease progression in relapsing multiple sclerosis in two phase 3 trials.
Medscape Medical News

source https://www.medscape.com/viewarticle/975368?src=rss

Comments

Popular posts from this blog

DC’s Harllee Harper Is Using Public Health Tools to Prevent Gun Violence. Will It Work?